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Abstract. Chronic inflammation has been considered an
important player in cancer proliferation and progression. High
salt (sodium chloride) levels have been considered a potent
inducer of chronic inflammation. In the present study, the
synergistic role of high salt with interleukin (IL)‑17 towards
induction of the inflammatory and angiogenic stress factor
vascular endothelial growth factor (VEGF)‑A was investigated. Stimulation of MCF‑7 breast cancer cells with high salt
(0.2 M NaCl) and sub‑minimal IL‑17 (1 ng/ml) enhanced the
expression of VEGF‑A (2.9 and 2.6‑fold, respectively, P<0.05)
compared with untreated cells. Furthermore, co‑treatment
with both high salt and sub‑minimal IL‑17 led to a 5.9‑fold
increase in VEGF‑A expression (P<0.01), thus suggesting a
synergistic role of these factors. VEGF‑A promoter analysis
and specific small interfering RNA knock‑down of transcription factors revealed that high salt induced VEGF‑A expression
through nuclear factor of activated T‑cells (NFAT)5, while
IL‑17 induced VEGF‑A expression via signal transducer and
activator of transcription (STAT)3 signaling mechanisms.
Treatment of normal human aortic endothelial cells with the
supernatant of activated MCF‑7 cells enhanced cell migration
and induced expression of migration‑specific factors, including
vascular cell adhesion protein, β1 integrin and cluster of
differentiation 31. These data suggest that high salt levels
synergize with pro‑inflammatory IL‑17 to potentially induce
cancer progression and metastasis through VEGF‑A expression. Therefore, low‑salt diet, anti‑NFAT5 and anti‑STAT3
therapies may provide novel avenues for enhanced efficiency
of the current cancer therapy.
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Introduction
A causal interlink between inflammation and cancer was first
suggested in the 19th century by Rudolf Virchow (1). Accumulating evidence over several decades has delineated underlying
molecular mechanisms between chronic inflammation and
cancer progression (2). Multiple studies have proposed that
inflammation‑induced genetic instability promotes tumor
progression (2). Inflammation also causes defective immune
surveillance and responses to anti‑cancer chemotherapy (3).
Chronic inflammation in the tumor microenvironment induces
the production of free radicals such as reactive oxygen and
nitrogen species, leading to oxidative damage and nitration of
DNA bases, which increases the risk of cancer initiation (4).
One of the key features of cancer progression and metastasis is
markedly enhanced inflammatory stress factors in the tumor
microenvironment (5).
One of the events linking inflammation and cancer is an
increase in inflammatory cytokines, including tumor necrosis
factor (TNF)α, interleukin (IL)‑6 and IL‑17, and stress growth
factors such as vascular endothelial growth factor (VEGF), in
the tumor microenvironment (6). The pro‑tumorigenic role of
IL‑17, an inflammatory cytokine, has also been implicated in
several types of cancer (7). In mice with carcinogen‑induced
skin tumors, deficient expression of IL‑17 receptor resulted in
a lower tumor incidence and a diminished tumor size (8). Typically, inflammatory cytokines induce their effect by activating
inflammatory transcription factors such as the Janus kinase
(JAK)/signal transducer and activator of transcription (STAT)
signaling pathway (9). Along with cytokines, chronic inflammation‑induced stress molecules such as VEGF are known to
be involved in cell proliferation, cell adhesion, inflammatory
cell recruitment, angiogenesis and cell migration, leading to
cancer progression (10). Specifically, the functions of VEGF in
cancer are not limited to angiogenesis alone (11). VEGF‑mediated signaling occurs in tumor cells and is known to contribute
to key aspects of tumorigenesis, including cancer initiation
and progression through its interaction with specific receptors,
leading to the regulation of trafficking and secretion of other
chemokines and extracellular matrix proteins (11).
A wide variety of environmental and infectious agents
have been attributed to increased risk of inflammation‑induced
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cancer progression (12). Dietary high salt intake has been
correlated with an increase in the incidence of cancers (13).
Traditionally, high salt levels have been correlated with cardiovascular disease and inflammatory injury in arteries (14). In
animal models, high sodium chloride levels have been demonstrated to cause excessive inflammatory activation, triggering
ischemia injury and end‑organ stress mediated by reactive
oxygen species and pro‑inflammatory cytokine secretion,
leading to irreversible cardiac cell damage (15,16). Importantly,
in the context of breast cancer, the sodium content of mammary
adenocarcinomas has been reported to be significantly higher
than in the normal mammary epithelium (17). However, in
that study, it was not clear if the increased sodium content
observed was intracellular or extracellular. Human studies
on gastric cancer suggested that excess sodium could cause
inflammation and stomach ulcers, which could lead to gastric
cancer (18). It is also important to understand that high sodium
content in mammary adenocarcinomas has been shown to be
significantly higher than that of normal lactating mammary
epithelium (19). Furthermore, a correlation between expression of sodium symporters and increased invasion capacity
of breast cancer has been previously suggested (20‑22). In the
present study, the synergistic effect of high sodium chloride
levels with pro‑inflammatory cytokines towards induction of
the expression of VEGF‑A, a crucial inflammatory and angiogenic stress factor that is important in tumor progression and
metastasis, is reported.
Materials and methods
Cell culture. The breast cancer cell line MCF‑7 (HTB‑22TM)
and normal human aortic endothelial cells (NHAECs;
PCS‑100‑011TM ) were obtained from the American Type
Culture Collection (ATCC; Manassas, VA, USA) and cultured
in cell basal essential medium (30‑2003; ATCC) along with
the medium supplements recommended by the manufacturer.
For stimulation studies, breast cancer cells were treated with
varying concentrations (0‑1,000 ng/ml) of IL‑17 (Thermo
Fisher Scientific, Inc., Waltham, MA, USA) or sodium chloride
supplement (0.2 M final concentration; Sigma‑Aldrich, St.
Louis, MO, USA) for 48 h. It is important to note that sodium
chloride concentration in regular cell culture basal medium
is 0.1 M. Therefore, to perform high salt studies (0.2 M), the
basal medium was supplemented with additional 0.1 M NaCl
to achieve a final concentration of 0.2 M. Specific small interfering (si)RNA (Santa Cruz Biotechnology, Inc., Dallas, TX,
USA) mediated gene knock‑down of STAT3 (sc‑29493) and
NFAT5 (sc‑43968). The knock‑down efficiency was measured
by reverse transcription‑quantitative polymerase chain reaction
(RT‑qPCR), and non‑specific siRNA (sc‑37007) was used as a
negative control. All experiments were performed in triplicate.
Western blot analysis. Western blot analysis was performed
as described previously (23,24). All primary and secondary
antibodies were obtained from Santa Cruz Biotechnology,
Inc., unless mentioned otherwise. All primary antibodies were
diluted to 1:200 and all secondary antibodies were diluted to
1:1,000. The following specific primary antibodies against
VEGF‑A (sc‑152), STAT3 (sc‑482), STAT5 (sc‑835), NFAT1
(sc‑7294), NFAT5 (sc‑13035), vascular cell adhesion protein

(VCAM; sc‑8304), β1 integrin (sc‑9970) and actin (sc‑10731)
were utilized. Phosphorylated proteins were probed with the
phospho (p)‑specific primary antibodies Ser‑727‑p‑STAT3
(s c ‑21876 ) a nd Se r‑155 ‑p ‑N FAT5 (SA B45 0 4718)
(Sigma‑Aldrich). The nitrocellulose membranes were
developed using a chemiluminescence kit (EMD Millipore,
Billerica, MA, USA) and analyzed using Universal Hood II
(Bio‑Rad Laboratories, Inc., Hercules, CA, USA). Densitometric analysis was performed using ChemiDoc XRS systems
software provided by Bio‑Rad Laboratories, Inc.
Messenger (m)RNA expression analysis. The expression
profiles of intracellular signaling genes in MCF‑7 cells were
analyzed using fluorescein amidite‑labeled RT‑qPCR primers
for VEGF‑A (Hs03929036_s1), NFAT5 (Hs00232437_m1),
STAT3 (Hs01051722_s1), glyceraldehyde 3‑phosphate dehydrogenase (GAPDH; Hs402869) and actin (Hs4333762T),
which were obtained from Applied Biosystems (Thermo Fisher
Scientific, Inc.), according to the manufacturer's protocol (25).
Briefly, total RNA was extracted from 106 cells using TRIzol
reagent (Sigma‑Aldrich). RNA samples were quantified by
their absorbance at 260 nm. The RNA was reverse transcribed,
and qPCR was subsequently performed in a final reaction
volume of 50 µl using LightCycler ® 480 Probes Master
(Roche Diagnostics, Indianapolis, IN, USA). Each sample
was analyzed in triplicate. Cycling conditions consisted of an
initial denaturation of 95˚C for 15 min, followed by 40 cycles
of 95˚C for 30 sec, followed by annealing/extension at 61˚C
for 1 min. Expression data were quantified using the 2‑ΔΔCq
method (26) and normalized to GAPDH expression.
Immunofluorescence microscopy. For staining of VEGF‑A,
50,000 MCF7 cells were grown on coverslips in 24‑well
plates (19). Cells were fixed with 4% paraformaldehyde (23).
Normal 2% goat serum in Dulbecco's phosphate‑buffered
saline (Thermo Fisher Scientific, Inc.) with 1% bovine
serum albumin (Sigma‑Aldrich) and 0.1% Tween 20 was
used for blocking and washing. The aforementioned specific
anti‑VEGF‑A primary antibody and a phycoerythrin‑conjugated antibody (cat no. 12-4739-81; eBioscience, Inc., San
Diego, CA, USA) were used for immunofluorescence, with
primary antibodies diluted to 1:10 and secondary antibodies
diluted to 1:40. The images were captured using an Eclipse
80i fluorescence microscope (Nikon Corporation, Tokyo,
Japan) and processed using Metamorph version 6.3r2 software
(Molecular Devices, LLC, Sunnyvale, CA, USA).
Plasmid constructs and luciferase reporter assay. For the
reporter constructs, the VEGF‑A promoter regions (‑2,000 to
+50 bp) were amplified from human genomic DNA (Zyagen,
San Diego, CA, USA) by PCR using iProof™ High‑Fidelity
DNA Polymerase (Bio‑Rad Laboratories, Inc.) (23). The PCR
products were subcloned into the pGL4.11[luc2P] vector
(Promega Corporation, Madison, WI, USA) upstream of a
luciferase gene using appropriate restriction sites. Putative
transcription factor binding sites were identified with the
Transcription Element Search System (TESS) algorithm
(http://www.cbil.upenn.edu/downloads/).
The transcription factor binding to the VEGF‑A promoter
was analyzed by luciferase assay as previously reported (20,23).
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Briefly, MCF‑7 cells (1x105) were transfected in 24‑well plates
with 1 µg pGL4.11[luc2P] luciferase reporter vector driven by
the VEGF‑A promoter, or with 2 µg control vector. For transfection of MCF‑7 cells, 0.2x105 cells/well were seeded into
a 24‑well plate and grown for 24‑48 h. Cells were harvested
48 h post‑transfection, and efficiency was measured by qPCR,
immunostaining and western blotting.
C h ro m a t i n ‑ i m m u n o p re c i p i t a t i o n (C h I P) a n d
co‑immunoprecitation (Co‑IP). ChIP and Co‑IP were
performed as previously described (20). For ChIP analysis to
identify the binding regions of NFAT5 and STAT3, ChIP‑IT
Express kit (Active Motif, Inc., Carlsbad, CA, USA) was utilized
according to the manufacturer's protocol and as previously
described (23). Control immunoglobulin (Ig)Gs, anti‑NFAT5
or anti‑STAT3 (1 µg) were used to immunoprecipitate the
DNA‑protein complexes. Specific VEGF‑A promoter regions
were amplified using PCR and resolved on 2% agarose gels.
PCR cycling conditions consisted of an initial denaturation
step at 95˚C for 3 min, followed by 35 cycles of 95˚C for 30 sec,
annealing at 60˚C for 30 sec and extension at 72˚C for 1 min.
For NFAT5 and STAT3 Co‑IP, proteins obtained from MCF‑7
cells were subjected to sodium dodecyl sulfate polyacrylamide
gel electrophoresis (4‑12% polyacrylamide gels) and immunoblotting. NFAT5 and STAT3 were detected with rabbit
anti‑NFAT5 and rabbit anti‑STAT3 antibodies, respectively.
The primary antibodies were diluted to 1:200 and secondary
antibodies were diluted to 1:1,000
Enzyme‑linked immunosorbent assay (ELISA). The secretory
extracellular VEGF‑A in the cell supernatant was quantitated
by ELISA according to the manufacturer's protocol (R&D
Systems, Inc., Minneapolis, MN, USA) (21). Due to the limitation of the detection system, the supernatant was diluted
1:1,000 and quantified with a standard curve using the manufacturer‑provided standards. Detection of the optical density
value at 450 nm was performed using EMax® Plus Microplate
Reader (Molecular Devices, LLC), and data analysis was
conducted using SoftMax Pro GxP software (version 5.4)
provided by Molecular Devices, LLC.
Cell migration assay. The migratory ability of NHAECs
following stimulation with the supernatant isolated from
various MCF‑7‑experimental cell culture conditions was
performed using Cultrex ® Cell Migration Assays (cat
no. 3465‑096‑K; R&D Systems, Inc.) according to the manufacturer's protocol. Briefly, serum‑starved NHAECs were placed
in the top chamber, and fresh 24‑h supernatant collected from
MCF‑7 cells that had been subjected to various experimental
cell culture conditions was placed in the bottom chamber, separated by a basement membrane‑coated separation membrane.
The migration ability was quantified following dissociation of
the cells from the membrane with the appropriate dissociation
buffers (provided in the Cultrex Cell Migration Assay) and
colorimetrically analyzed at 595 nm.
Flow cytometry. The expression of cluster of differentiation
(CD)31 on NHAECs was analyzed by flow cytometry using
appropriated primary and fluorescein isothiocyanate‑labelled
secondary antibodies (25). Samples were analyzed using
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a FACSCalibur/LSR II flow cytometer (BD Biosciences,
Franklin Lakes, NJ, USA), and cell sorting was performed
with a FACSVantage cell sorter (BD Biosciences). Data
were analyzed using FACSDiva™ software (version 8.0.1;
BD Biosciences). Gates were set according to isotype controls.
Statistical analysis. Data were expressed as the mean ± standard error of the mean from four independent experiments.
Statistical differences between the means were analyzed using
a paired or unpaired Student's t test. P<0.05 was considered to
indicate a statistically significant difference. All analyses were
conducted using Origin version 7.0 (OriginLab, Northampton,
MA, USA) or GraphPad version 5 software (GraphPad Software, Inc., LaJolla, CA, USA).
Results
Enhanced expression of VEGF‑A following co‑stimulation
of MCF‑7 cells with high sodium chloride and sub‑minimal
IL‑17 levels. Although VEGF was initially considered to be a
vascular permeability factor and an endothelial cell‑specific
mitogen, multiple lines of evidence convincingly suggest
its critical role as an autocrine‑signaling factor in solid
tumors, including breast cancer (22). Previous studies have
reported that IL‑17 induces the expression of VEGF‑A in
solid tumors (27). In line with this evidence, preliminary
experiments conduced by the present authors on MCF‑7 breast
cancer cells demonstrated a significantly higher expression of
VEGF‑A following stimulation with IL‑17 at concentrations
>100 ng/ml, but minimal response (<20%) at concentrations
<10 ng/ml (data not shown). To determine the specific role
of high sodium chloride levels (referred to as high salt) in a
pro‑inflammatory microenvironment, initial cell viability
studies were performed, which demonstrated <30% cell
viability at NaCl concentrations >0.25 M, while >95% cell
viability was maintained at 0.15 and 0.2 M NaCl in the culture
medium (data not shown). Therefore, in all the experiments
described in the present study, 0.2 M NaCl was used for high
salt condition, and 1 ng/ml IL‑17 was used for sub‑minimal
IL‑17 concentration.
As VEGF‑A is a key inflammatory stress molecule
and biomarker, experiments were performed in the present
study to determine the role of high salt synergising with the
pro‑inflammatory cytokine effect of IL‑17 on the expression
of VEGF‑A protein. For that purpose, the breast cancer cell
line MCF‑7 was treated with either high salt (0.2 M NaCl),
IL‑17 (1 ng/ml) or a combination of both. As shown in Fig. 1A,
western blot analysis of the cellular extract from MCF‑7 cells
demonstrated an increased expression of VEGF‑A following
co‑treatment with high salt and sub‑minimal IL‑17. This was
further verified by intracellular immunocytochemical staining
of MCF‑7 cells for VEGF‑A (Fig. 1B). Quantitative mRNA
analysis of VEGF‑A (Fig. 1C) demonstrated that, under
basal conditions, there was minimal expression of VEGF‑A
mRNA transcript (2.1±0.6‑fold) compared with the GAPDH
control transcript. However, following treatment with either
high salt or sub‑minimal IL‑17 alone, there was a significant
elevation of VEGF‑A mRNA transcription (6.1±1.3 and
5.4±0.8‑fold, respectively, P<0.05). Co‑treatment with both
high salt and sub‑minimal IL‑17 demonstrated a 15.7±2.9‑fold

936

AMARA et al: INDUCTION OF VEGF‑A BY HIGH SALT AND IL-17

increased VEGF‑A transcript expression (P<0.05) over the
basal conditions. These data were further confirmed by
ELISA‑based quantitative analysis of the supernatant from
the aforementioned conditions to measure the secretion of
VEGF‑A protein by MCF‑7 cells (Fig. 1D). Importantly,
treatment with equimolar mannitol concentrations (0.1 M
NaCl + 0.1 M mannitol) demonstrated no enhanced expression of VEGF‑A (2.5±0.9‑fold, P>0.70) over basal conditions.
These data indicate that high salt and IL‑17 exert a synergistic
effect. Furthermore, as the synergistic effect was higher than
the individual conditions alone, these results strongly suggest
a possibility of two different signaling mechanisms separately
induced by high salt and IL‑17.
Transcription factors NFAT5 and STAT3 induce VEGF‑A
expression following co‑stimulation with high salt and IL‑17.
Based on the aforementioned findings (Fig. 1), experiments
were performed to determine the transcription factors involved
in the signaling events mediated by high salt and IL‑17 that
led to increased expression of VEGF‑A. The present authors
previously demonstrated that STAT3 mediates IL‑17‑induced
pro‑inflammatory signaling (23). NFAT5, also known as
tonicity‑responsive enhancer binding protein (TonEBP), which
is a mediator of osmotic stress and immune regulation, has also
been observed to be upregulated in breast cancer (28). Therefore, various transcription factors were initially analyzed by
RT‑qPCR, and NFAT5 and STAT3 demonstrated significantly
enhanced expression following treatment with high salt and
IL‑17. The other transcription factors tested that did not induce
a significant change under the current experimental conditions
were NFAT1‑4 and STAT1, ‑2, ‑4 and ‑6 (data not shown).
Western blot and phosphoblot studies (Fig. 2A) demonstrated
enhanced expression and phosphorylation of NFAT5 in MCF‑7
cells following treatment with high salt (0.2 M NaCl) for
60 min, while stimulation with sub‑minimal IL‑17 (1 ng/ml)
enhanced the expression and phosphorylation of STAT3.
However, co‑treatment with high salt and sub‑minimal IL‑17
led to increased expression and phosphorylation of both NFAT5
and STAT3. Quantitative analysis by RT‑qPCR demonstrated
that there was a 3.4‑fold upregulation of total and phosphorylated NFAT5 (Fig. 2B and C) following treatment with high
salt, which did not increase further upon co‑treatment with
both high salt and sub‑minimal IL‑17. Similarly, there was a
3‑fold upregulation in total and phosphorylated STAT3 levels
(Fig. 2D and E) following treatment with sub‑minimal IL‑17,
which did not increase further upon co‑treatment with high
salt and sub‑minimal IL‑17. These data support the earlier
assertion that high salt and IL‑17 potentially induce VEGF‑A
expression through two different signaling pathways.
To confirm that high salt and IL‑17 induce separate
signaling pathways that result in the induction of VEGF‑A
expression, siRNA knockdown experiments specific for
NFAT5 and STAT3 were performed. Western blot analysis
(Fig. 2F) demonstrated that siRNA knock‑down of NFAT5
and STAT3 individually, following co‑treatment with high
salt and sub‑minimal IL‑17, led to reduced intracellular
expression of VEGF‑A. As expected, combined knock‑down
of both NFAT5 and STAT3 synergistically diminished
VEGF‑A expression. This was further verified by immunocytochemical analysis (Fig. 2G). Quantitative ELISA‑based

analysis of VEGF‑A secretion (Fig. 2I) demonstrated
that NFAT knock‑down reduced VEGF expression to
137±49 pg/ml, while STAT3 knock‑down reduced VEGF
expression to 152±41 pg/ml in high salt and sub‑minimal
IL‑17‑co‑treated MCF‑7 cells, where VEGF‑A expression
was 562±73 pg/ml prior to treatment. Taken together, these
data confirm that high salt and IL‑17 induce two different
signaling mechanisms leading to enhanced expression of the
inflammatory stress molecule VEGF‑A.
NFAT5 and STAT3 bind to the VEGF‑A promoter region at
‑1,471 and ‑840 bp upstream of the open reading frame. To
determine the role of high salt and IL‑17 in VEGF‑A gene
transcription, the luciferase reporter construct containing
the ‑2,000 to +50 bp region of the human VEGF‑A gene
promoter was transfected into MCF‑7 breast cancer cells.
These luciferase‑transfected cells were treated with either
high salt, sub‑minimal IL‑17 or both, and luciferase activity
was recorded. An increase in VEGF‑A reporter activity was
observed following individual stimulation with high salt
(7.2‑fold, Fig. 3A) and sub‑minimal IL‑17 (6.4‑fold, Fig. 3B)
over control null‑luciferase vector‑transfected cells. Further
co‑treatment with both high salt and sub‑minimal IL‑17
produced a 25.2‑fold increase (Fig. 3C) in luciferase activity
compared with untreated cells. These data were in line with
the results described in Fig. 2, thus supporting the hypothesis that high salt and IL‑17 work synergistically to enhance
VEGF‑A expression.
To specifically identify the putative DNA binding
sequences for NFAT5 and STAT3 on the VEGF‑A promoter,
a computational analysis of the ‑2,000 to +50 bp region of
the VEGF‑A promoter was performed using TESS. This
analysis identified two putative DNA binding sites for
NFAT5 (TGGAAA at ‑1,471 and ‑1,809 bp) and two putative DNA binding sites for STAT3 (TTCCCAA A/TTTCCA
AA at ‑840 and ‑622 bp) (Fig. 3A). To determine whether
NFAT5 and STAT3 regulate VEGF‑A expression in MCF‑7
cells, these cells were transfected with the mutant VEGF‑A
promoter reporter construct and treated with high salt, IL‑17
or both (Fig. 3A‑C). As shown in Fig. 3A, following treatment with high salt, the putative NFAT5 binding site mutant
construct (*‑1,474‑73, GA to *TC) exhibited a significant
decrease (≤66% loss of activity) in reporter activity compared
with the native VEGF‑A reporter activity. However, the other
putative NFAT5 binding site mutant construct (*‑1,812‑11,
GA to *TC) did not display any change in VEGF‑A promoter
activity, thus suggesting that the NFAT5 binding domain is
located at ‑1,471 bp on the VEGF‑A promoter. Similarly,
following treatment with sub‑minimal IL‑17 (Fig. 3B), the
putative STAT3 (TTCC CAA A or TTTC CAA A) binding
mutant construct (*‑843‑842, CA to *TG) exhibited a significant decrease (≤71% loss of activity) in reporter activity
compared with the native VEGF‑A reporter activity, while
the other putative STAT3 binding mutant construct (*‑625‑24,
CA to *TG) did not exhibit any change in VEGF‑A promoter
activity, thus suggesting that the putative STAT3 binding
domain is located at ‑1,471 bp. As expected, these two
mutants demonstrated the highest loss of activity following
co‑treatment with high salt and sub‑minimal IL‑17 (Fig. 3C),
thus strongly suggesting a synergistic mechanism of action
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Figure 1. Induction of VEGF‑A expression in MCF‑7 breast cancer cells following stimulation with high salt and sub‑minimal IL‑17. (A) Western blot analysis
of VEGF‑A expression in MCF‑7 cells following treatment with high salt (0.2 M NaCl), IL‑17 (1 ng/ml) or both (0.2 M NaCl and 1 ng/ml IL‑17). Of note, the
regular complete medium used in the present study contained 0.1 M NaCl, and equimolar mannitol (0.1 M NaCl + 0.1 M mannitol) was used as a negative
control. The cell lysates were probed with appropriate primary and secondary antibodies. (B) Immunocytostaining of MCF‑7 cells for VEGF‑A. VEGF‑A
was probed with rabbit anti‑human primary antibody at 1:100, and later probed with phycoerythrin‑conjugated goat anti‑rabbit secondary antibody at 1:200.
(C) VEGF‑A messenger RNA expression was analyzed by reverse transcription‑quantitative polymerase chain reaction. Quantitation was performed by the
2−ΔΔCq method and normalized to glyceraldehyde 3-phosphate dehydrogenase expression. (D) Enzyme-linked immunosorbent assay‑based analysis of VEGF‑A
in the supernatant of the MCF‑7 cells following treatment with the conditions mentioned above. Data are represented as mean values ± standard error of the
mean from four independent experiments. Statistical significance was analyzed with the Student's t test, *P<0.05; #P>0.05. VEGF, vascular endothelial growth
factor; mRNA, messenger RNA; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IL, interleukin.

between NFAT5 and STAT3 transcription factors in regulating VEGF‑A expression.
To determine whether NFAT5 and STAT3 bind to adjacent DNA binding sites on the VEGF‑A promoter to form
transcriptional‑activation DNA‑protein complexes, following
high salt, IL‑17 or combined treatment, MCF‑7 cells were
immunoprecipitated with anti‑NFAT5, anti‑STAT3 or control
IgGs. The results of ChIP and PCR analysis using primers
specific for the VEGF‑A promoter regions ‑2,000 to ‑1,751 bp,
‑1,500 to ‑1,251 bp, ‑1,000 to ‑751 bp, ‑700 to ‑450 bp, and
control primers for the ‑250 to +50 bp region of the actin

promoter (Fig. 3E, black bars), demonstrated that NFAT5
and STAT3 bind to the VEGF‑A promoter at the ‑1,500 to
‑1,251 bp and ‑1,000 to ‑751 bp regions, respectively (Fig. 3D).
The DNA binding pattern of NFAT5 and STAT3 strongly
correlates with the locations of the consensus binding sites
on the VEGF‑A promoter determined by luciferase reporter
activity (Fig. 3A‑C). ChIP with control IgGs did not enrich
VEGF‑A promoter regions, demonstrating the specificity
for these transcription factors. No binding was observed in
PCRs conducted with primers specific for the ‑250 to +50 bp
region of the actin promoter, which lacks these binding sites
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Figure 2. NFAT5 and STAT3 transcription factors were induced in MCF‑7 cells following stimulation with high salt and sub‑minimal IL‑17, respectively.
(A) Western blot analysis was performed to determine the protein expression levels of NFAT5 (170 kDa), p‑NFAT5 (170 kDa), NFAT1 (140 kDa), STAT3
(86 kDa), p‑STAT3 (86 kDa), STAT5 (92 kDa) and actin (43 kDa), both total and active phosphorylated forms, after 30 min of stimulation with high salt,
sub‑minimal IL‑17 or both. Quantitative mRNA expression of (B) NFAT5, (C) STAT3, (D) p‑NFAT5 and (E) p‑STAT3 by RT‑qPCR was analyzed after 60 min
of stimulation with high salt, sub‑minimal IL‑17 or both. Quantitation was performed with the 2−ΔΔCq method normalized to GADPH expression. (F) Western
blot analysis of VEGF‑A expression in MCF‑7 cells following stimulation with high salt and IL‑17, along with NFAT5 and STAT3 knock‑down by specific
siRNA. Scrambled siRNA was used as negative control. Specific NFAT5 and STAT3‑siRNA treatment resulted in decreased expression of NFAT5 and STAT3
transcription factors, respectively. (G) Immunocytostaining of MCF‑7 cells for VEGF‑A following treatment with both high salt and sub‑minimal IL‑17, and
specific siRNA knock‑down of NFAT5 and STAT3. (H) VEGF‑A mRNA expression was analyzed by RT‑qPCR in MCF‑7 cells following stimulation with
high salt and IL‑17, along with NFAT5 and STAT3 knock‑down by specific siRNA. Quantitation was performed with the 2−ΔΔCq method normalized to GADPH
expression. (I) Enzyme-linked immunosorbent assay‑based analysis of VEGF‑A in the supernatant collected from MCF‑7 cells following stimulation with
high salt and IL‑17, along with NFAT5 and STAT3 knock‑down by specific siRNA. Data are represented as mean values ± standard error of the mean from four
independent experiments. Statistical significance was analyzed by the Student's t test, *P<0.05; #P>0.05. VEGF, vascular endothelial growth factor; mRNA,
messenger RNA; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IL, interleukin; NFAT, nuclear factor of activated T-cells; STAT, signal transducer
and activator of transcription; p‑, phosphorylated; siRNA, small interfering RNA; RT‑qPCR, reverse transcription‑quantitative polymerase chain reaction.

(Fig. 3D). Furthermore, the protein‑protein complexes were
immunoprecipitated (Fig. 3E) and probed with anti‑STAT3
or anti‑NFAT5 antibodies on western blotting. This supported

the ChIP findings that NFAT5 and STAT3 were complexed
together on the VEGF‑A promoter. Taken together, these
data clearly demonstrate that the transcription factors NFAT5
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Figure 3. Binding sites of the transcription factors NFAT5 and STAT3 on the VEGF‑A promoter to induce downstream gene transcription. (A) Transcription
Element Search System‑based computational analysis of ‑2,000 bp upstream of the VEGF‑A open reading frame. Putative binding domains for NFAT5 and
STAT3 at ‑1,809, ‑1,471, ‑840 and ‑622 bp were predicted to contain consensus sequences on the VEGF‑A promoter. MCF‑7 cells were transfected with a luciferase reporter driven by constructs of the VEGF‑A promoter (‑2,000 to +50 bp; mutation *Δ‑1,812‑11 bp/‑2,000 to +50 bp; and mutation *Δ‑1,474‑73 bp/‑2,000
to +50 bp) construct, and stimulated with high salt. (B) MCF‑7 cells were transfected with luciferase reporters driven by constructs of the VEGF‑A promoter
(‑2,000 to +50 bp; mutation *Δ‑843‑42 bp/‑2,000 to +50 bp; and mutation *Δ‑625‑24 bp/‑2,000 to +50 bp) construct, and stimulated with IL‑17. (C) MCF‑7
cells were transfected with luciferase reporters driven by constructs of the VEGF‑A promoter (‑2,000 to +50 bp; mutation *Δ‑1,474‑73 bp/‑2,000 to +50 bp;
mutation *Δ‑843‑42 bp/‑2,000 to +50 bp; or both mutations) construct, and stimulated with high salt and IL‑17. Luciferase activity was measured 48 h after
transfection and normalized to a Renilla luciferase internal control. The numbers indicate fold‑change over the control vector. (D) VEGF‑A promoter with
binding sites for NFAT5 and STAT3. The four black horizontal bars represent the regions amplified by polymerase chain reaction with specific primers for the
‑2,000 to ‑1,751 bp, ‑1,500 to ‑1,251 bp, ‑1,000 to ‑751 bp and ‑700 to ‑450 bp regions of the VEGF‑A promoter, and the negative control ‑250 to +50 bp region
of the ACT1a promoter. Chromatin was immunoprecipitated with anti‑NFAT5, anti‑STAT3 or isotype control immunoglobulin G antibodies from MCF‑7
cells following stimulation with both high salt and IL‑17. The first three lanes represent chromatin‑immunoprecipitation, while the fourth lane represents input
chromatin. (E) Co‑immunoprecitation of the protein‑complex extracted by anti‑STAT3 and anti‑NFAT5 antibodies, and western blot analysis to probe with the
opposite antibody (upper panel, probed with NFAT5 antibody and protein complex pulled‑down with anti‑STAT3 antibody; lower panel, probed with STAT3
antibody and protein complex pulled‑down with anti‑NFAT5 antibody). Data are represented as mean values ± standard error of the mean from four independent experiments. Statistical significance was analyzed with the Student's t test, *P<0.05; #P>0.05. Luc, luciferase; IL, interleukin; ACT1a, actin‑1a; NFAT,
nuclear factor of activated T-cells; STAT, signal transducer and activator of transcription; Ig, immunoglobulin; VEGF, vascular endothelial growth factor.

and STAT3 synergistically interact and are part of a larger
transcription‑regulatory complex enhancing the VEGF‑A
gene expression.
Enhanced cell migration following activation of NHAECs
with VEGF‑A supernatant. As VEGF‑A has been implicated in tumor cell migration, the potential upregulation
of cell migration and surface proteins that mediate cell
migration in NHAECs was determined (29). MCF‑7 cells
were pre‑stimulated for 48 h with high salt, sub‑minimal
IL‑17 or both, and later washed. Supernatant collected from
24 h post‑stimulation cultured cells under basal medium

conditions was used to determine the migration efficiency
of NHAECs. Cell migration was studied utilizing a migration chamber with NHAECs coated in the top chamber with
serum‑starved medium, while the bottom chamber was
filled with supernatant collected from 24 h post‑stimulated
MCF‑7 cells. As shown in Fig. 4A and B, following treatment of NHAECs for 24 h with supernatant of MCF‑7 cells
subjected to combined pre‑stimulation with high salt and
IL‑17, there was increased migration of NHAECs [optical
density (OD), 0.62±0.19] compared with individual stimulation with only high salt (OD, 0.28±0.09) or sub‑minimal
IL‑17 (OD, 0.21±0.07). It is important to note that there was
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Figure 4. Induction of cell migration and migration‑specific protein expression following activation of NHAECs with VEGF‑A‑rich supernatant. (A) Cell
migration analysis after 24 h of culture in the migration chambers. The top chamber was coated with NHAECs placed in serum‑starved medium. The lower
chamber was filled with fresh 24‑h supernatant from MCF‑7 cells following pre‑stimulation for 48 h with high salt, IL‑17 or both. To determine the specific
role of VEGF‑A, in the fifth panel, the lower chamber was filled with supernatant (as described above) with both high salt and IL‑17, along with VEGF‑A
neutralization with immunoglobulin G2b monoclonal antibody at 1:1,000 dilution. (B) Optical density at 595 nm of the cells collected from the bottom
chamber following 24 h of culture (C) Western blot analysis of NHAECs probed for VCAM (110 kDa) and β1 integrin (130 kDa) following treatment with
supernatant from MCF‑7 cells stimulated with high salt, IL‑17 or both for 24 h. (D) Densitometry analysis of the western blotting results for VCAM normalized
to basal expression. (E) Densitometry analysis of the western blotting results for β1 integrin normalized to basal expression. (F) Flow cytometry analysis of
the expression of CD31 on NHAECs subjected to the stimulation conditions mentioned above. FL-1 refers to the single fluorescence channel maintained for
phosphatidylethanolamine-labeled probing of CD31. The isotype control is represented by the grey line, while CD31 is represented by the black line. Data are
presented as mean values ± standard error of the mean from four independent experiments. Statistical significance was analyzed by the Student's t test, *P<0.05;
#
P>0.05. IL, interleukin; VEGF, vascular endothelial growth factor; mAb, monoclonal antibody; OD, optical density; AU, arbitrary unit; VCAM, vascular cell
adhesion protein; CD, cluster of differentiation; NHAECs, normal human aortic endothelial cells.

a significant inhibition of NHAEC migration when blocked
with anti‑VEGF‑A monoclonal IgG2b antibody (1:1,000 dilution; cat no. MAB293; R&D Systems) addition to the
supernatant collected from high salt and IL‑17‑co‑treated
MCF‑7 cells. This supports the hypothesis that cell migration was mediated by VEGF‑A secreted from pre‑stimulated
MCF‑7 cells. Furthermore, analysis of the expression of the

migratory molecules VCAM (Fig. 4C), β1 integrin (Fig. 4D)
and CD31 (Fig. 4E) demonstrated enhanced expression of
these migratory molecules in NHAECs upon treatment with
supernatant from pre‑stimulated MCF‑7 cells with both high
salt and sub‑minimal IL‑17. These findings confirm that high
salt synergised with the pro‑inflammatory cytokine‑mediated
expression of the stress factor VEGF‑A.
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Discussion
Although high salt has been traditionally associated with
cardiovascular diseases, recent evidence suggests that high
salt levels also increase the risk of cancer (13). The tumor
microenvironment is known to have high concentrations of
several inflammatory cytokines, including IL‑6, IL‑17 and
TNFα (30). High salt is a potent inducer of chronic inflammatory response through the activation of reactive oxygen and
nitrogen species (31). Furthermore, chronic inflammation is
considered a key initiator for several solid tumors, including
breast cancer (2). As early as in the 1980s, high salt and sodium
transporters in the tumor tissue were suggested to play a critical role in breast cancer progression and metastasis (17). More
recently, a direct inflammatory effect of salt on immune cells
such as T‑cells and macrophages has been reported (32,33).
However, the exact molecular mechanisms by which high salt
induces inflammation in the tumor microenvironment are not
yet defined.
The role of osmotic stress in inflammatory processes has
been extensively suggested in the scientific literature (34).
Culture of human peripheral blood cells under hyperosmotic
conditions (330‑410 mOsm/kg H2O) has been shown to induce
expression of pro‑inflammatory cytokines such as IL‑1 and
IL‑8 (35). Notably, patients with Crohn's disease, an inflammatory bowel disease, present with substantially higher
osmolality of the faecal fluid compared with control subjects
(490 vs. 340 mOsm/kg H2O), which strongly correlates with the
intestinal histopathological score (36). In the tumor microenvironment, osmotic stress is considered to trigger receptor
tyrosine kinases such as epidermal growth factor receptor,
resulting in activation of the erbB‑2/neu proto‑oncogene (37).
All the above lines of evidence suggest that hypernatremia
or high sodium induce osmotic stress, which in‑turn leads
to an inflammatory response. The current study attempted
to evaluate the direct inflammatory effect of high salt on
hyperosmolarity‑induced events (by performing control
equimolar mannitol studies), in order to demonstrate that
high salt in the cell microenvironment could directly induce
expression of VEGF, a known inflammatory biomarker (10).
However, the current results do not completely preclude a
high salt‑mediated, osmotic‑stress‑induced VEGF expression,
which requires further studies.
Although VEGF was originally discovered as a vascular
and endothelial‑activating factor, several studies have conclusively suggested its critical role in tumor cell progression
and metastasis (10). Several isoforms of VEGF have been
reported, including VEGF121, VEGF165 and VEGF189, (38). In
addition, cell‑specific VEGF isoforms, including VEGF‑A
(present in the majority of cell types) (10), VEGF‑B (present
in neurons and retina) (39) and VEGF‑C (present in macrophages) (40) have been reported. It is important to note that
anti‑VEGF monoclonal antibody‑based therapeutic strategies
are currently employed to treat cancers (41). It has also been
suggested that direct stimulation of tumor cells by VEGF may
inhibit apoptosis and increase their resistance to conventional
chemotherapy and radiotherapy administered in cancer
treatment (42). Therefore, understanding the mechanisms of
expression of VEGF is crucial for anti‑cancer therapeutic
success. It has been well documented that VEGF exerts
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autocrine and paracrine pro‑cancer effects in breast cancer
through activation of cancer‑specific AKT/phosphoinositide
3‑kinase signaling mechanisms (43). In the present study, the
potential role of high salt in the presence of pro‑inflammatory
cytokines towards induction of VEGF has been investigated.
Notably, the present results support the previous reports that
inflammatory stimulus induces VEGF expression in MCF‑7
breast cancer cells (Fig. 1). Therefore, the present authors
propose a novel role for high salt in the tumor microenvironment as an important mediator of VEGF expression.
Furthermore, this expressed VEGF was observed to be critical
for endothelial cell migration (Fig. 4). Taken together, the
present data suggest that high salt plays a key inflammatory
role in VEGF‑mediated cancer cell proliferation.
The transcription factor NFAT5 is the most recently identified member of the NFAT family (44). Originally, NFAT5
was termed TonEBP or osmotic response element‑binding
protein (34). In humans, previous studies addressing the function of NFAT5 were primarily focused on the kidney medulla,
since renal cells are physiologically exposed to highly elevated
interstitial osmolalities (34). NFAT5 is considered to exert
an osmoprotective function in the kidney (33). However, a
number of studies supported the notion that NFAT5 is important in immune responses and lymphocyte activation (45). A
recent study by Remo et al (28), utilizing in silico modeling
and gene expression analysis on breast cancer patients (n=197),
reported an enhanced expression of NFAT5 in inflammatory
breast cancer. In line with that study, the present findings have
demonstrated that high salt induces VEGF expression through
specific upregulation of the transcription levels of NFAT5
(Figs. 2 and 3), a known key molecule in breast cancer (27). In
addition, the present study identified a putative NFAT5 binding
domain on the VEGF‑A promoter at ‑1,471 bp upstream of
the VEGF‑A coding gene (Fig. 3). These data clearly suggest
that high salt mediates a direct inflammatory response in the
cancer microenvironment.
The present study has demonstrated that high salt synergises with IL‑17, a pro‑inflammatory cytokine, towards the
expression of the inflammatory molecule VEGF‑A (27).
The role of IL‑17 in cancer progression is well established.
Several reports, including a previous study by the present
authors, have demonstrated that IL‑17 exerts its inflammatory response through activation of the STAT3 transcription
factor signaling pathway (23). STATs comprise a family
of cytoplasmic transcription factors that mediate intracellular signaling, which is usually generated by membrane
receptor‑ligand interactions (45). Numerous studies have
demonstrated constitutive activation of STAT3 in a wide
variety of human tumors (46). There is an increasing body of
evidence suggesting that aberrant STAT3 signaling promotes
initiation and progression of human cancers (46). Suppression of STAT3 activation has been reported to induce tumor
cell death by apoptosis (45). In line with previous reports,
the present authors have identified a putative STAT3 binding
domain (Fig. 3) at ‑840 bp upstream of the VEGF‑A coding
gene. Furthermore, the results of the luciferase reporter assay
conducted in the present study strongly suggest that high
salt exerts its synergistic effect with the pro‑inflammatory
cytokine IL‑17 through activation of two independent but
synchronous signaling pathways via NFAT5 and STAT3,
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in order to induce the expression of VEGF‑A. However, the
current study has limitations due to the experimental use and
analysis of only one breast cancer cell line. Nonetheless, the
authors consider that the conclusions of the present study are
applicable to other solid tumors, which requires further validation in other tumor cell lines (particularly breast cancer),
along with animal model studies.
In conclusion, in spite of significant advances, current
anti‑cancer therapies have a great scope for improvement (6).
The current data suggest an important role for NFAT5 and
STAT3 signaling in high salt‑mediated cancer cell proliferation and migration. The authors propose a low‑salt diet, and
supplementing anti‑VEGF therapy with anti‑NFAT5 and
anti‑STAT3 therapies, as a future direction for efficient cancer
therapy. However, further clinical and basic biomedical studies
are required to validate these observations.
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